Pharmicell Co., Ltd. (KRX:005690)

Market Cap	748.85B
Revenue (ttm)	23.94B
Net Income (ttm)	-26.78B
Shares Out	60.00M
EPS (ttm)	-613.75
PE Ratio	n/a
Forward PE	n/a
Dividend	20.00 (0.16%)
Ex-Dividend Date	Dec 27, 2024

Volume	412,792
Average Volume	1,367,928
Open	12,860
Previous Close	12,860
Day's Range	12,530 - 12,860
52-Week Range	4,300 - 14,200
Beta	0.56
RSI	50.15
Earnings Date	n/a

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hear...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1968
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005690

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.